Zacks Investment Research on MSN1d
Here's Why you Should Retain Nevro Stock in Your Portfolio Now
Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring ...
Zacks Investment Research on MSN15d
Nevro Q4 Earnings & Revenues Beat Estimates, Gross Margin Down
Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss of 15 cents. The Zacks Consensus Estimate is pegged at a loss per share of ...
abc2716d
Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results
Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful ...
Mena FN17d
Nevro Reports Fourth-Quarter And Full-Year 2024 Financial Results
REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO ), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of ...